A phase III Children’s Oncology Group randomized controlled trial of the IGF-1R antibody ganitumab in combination with standard of care chemotherapy for children with metastatic Ewing sarcoma unfortunately showed no benefit in event-free survival and increased toxicity in the experimental arm [185]. Here, IGF1R is linked to Ewing sarcoma.